Single-product orthopedic startups can innovate fast, but they need FDA clearance and proven clinical superiority to become acquisition targets. Ardylons and Entebones expanded modestly before being bought by larger companies, showing how de-risked startups attract strategic buyers.
Chapters
It's a whole different way to do a business, which tells you that that space is pretty high on the bell curve of innovation. And I think it's a great discussion, single product companies versus multi-product companies.
And I think if you let these little companies sort of de-risk, you know, kind of the next thing, you know, it's gotta do something different. But at the same time, if you can do something different, and you can, you know, get the money to prove it, get it through the FDA and start, you know, getting it into clinical use and you can demonstrate that you've got something that's really better, then I think the strategics will pick it up in a heartbeat. And I think you've seen, you know, companies and maybe, maybe these don't exactly fit what Kyle is saying about a one product, but you've got the Ardylons, you've got the Entebones, you know, you've got companies that have a little bigger portfolio, not just one product, but a little bit bigger portfolio that are getting snapped up and they're, you know, I think that's how innovation is going to happen for the, for the big companies anymore.